{"id":"laba-lama-or-placebo-inhalation","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":{"chemblId":"CHEMBL5970128","moleculeType":null,"molecularWeight":"607.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Long-acting beta-2 agonists (LABA) increase intracellular cAMP to promote airway smooth muscle relaxation, while long-acting muscarinic antagonists (LAMA) block acetylcholine-mediated bronchoconstriction. Together, these complementary mechanisms provide sustained bronchodilation over 24 hours, improving airflow and reducing symptoms in obstructive airway diseases.","oneSentence":"LABA/LAMA combination provides dual bronchodilation by stimulating beta-2 adrenergic receptors (LABA) and blocking muscarinic M3 receptors (LAMA) to relax airway smooth muscle.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:51:21.262Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"},{"name":"Asthma maintenance therapy (LAMA/LABA combinations)"}]},"trialDetails":[{"nctId":"NCT04718389","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-26","conditions":"Asthma","enrollment":1719},{"nctId":"NCT02948959","phase":"PHASE3","title":"Evaluation of Dupilumab in Children With Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-04-21","conditions":"Asthma","enrollment":408},{"nctId":"NCT03250689","phase":"PHASE2","title":"Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-11-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":19},{"nctId":"NCT04509661","phase":"PHASE4","title":"Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2020-09-01","conditions":"Bronchiectasis Adult","enrollment":200},{"nctId":"NCT02814656","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-22","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":24},{"nctId":"NCT02796651","phase":"PHASE2","title":"Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-30","conditions":"Chronic Obstructive Pulmonary Disease - COPD","enrollment":132},{"nctId":"NCT01772134","phase":"PHASE3","title":"Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":617},{"nctId":"NCT03159442","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-06-19","conditions":"Chronic Obstructive Pulmonary Disease - COPD","enrollment":25},{"nctId":"NCT00976144","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":16},{"nctId":"NCT01772147","phase":"PHASE3","title":"Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":608}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":469,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Inhaled dual Bronchodilator"],"phase":"marketed","status":"active","brandName":"LABA/LAMA or Placebo inhalation","genericName":"LABA/LAMA or Placebo inhalation","companyName":"Shanghai Pulmonary Hospital, Shanghai, China","companyId":"shanghai-pulmonary-hospital-shanghai-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LABA/LAMA combination provides dual bronchodilation by stimulating beta-2 adrenergic receptors (LABA) and blocking muscarinic M3 receptors (LAMA) to relax airway smooth muscle. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy, Asthma maintenance therapy (LAMA/LABA combinations).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}